Aktis Oncology initiated with a Buy at BofA

BofA initiated coverage of Aktis Oncology (AKTS) with a Buy rating and $34 price target Following a strong public debut, the firm sees further potential upside for shares driven by the company’s differentiated tumor targeting technology with a highly efficacious radioisotope as well as biologically derisked targets, the analyst tells investors. The firm models greater than $8B in peak sales across the pipeline, if assets are approved, the analyst added.